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Original Article

Randomized Trial of the Efficacy and Safety of
Berotralstat (BCX7353) as an Oral Prophylactic
Therapy for Hereditary Angioedema: Results of
APeX-2 Through 48 Weeks (Part 2)
H. James Wedner, MDa, Emel Aygören-Pürsün, MDb, Jonathan Bernstein, MDc, Timothy Craig, DOd,
Richard Gower, MDe, Joshua S. Jacobs, MDf, Douglas T. Johnston, DOg, William R. Lumry, MDh, Bruce L. Zuraw, MDi,
Jessica M. Best, DHS, PAj, Heather A. Iocca, PhDj, Sharon C. Murray, PhDj, Bhavisha Desai, PharmDj, Eniko Nagy, MDj,
William P. Sheridan, MBBSj, and Sorena Kiani-Alikhan, MBPhDk St. Louis, Mo; Cincinnati, Ohio; Hershey, Pa; Spokane, Wash;
Walnut Creek and San Diego, Calif; Charlotte and Durham, NC; Dallas, Texas; Frankfurt, Germany

What is already known about this topic? Berotralstat (BCX7353), a novel oral agent for prophylaxis of hereditary
angioedema attacks, was shown to be effective and have a favorable beneﬁt-to-risk proﬁle over 24 weeks in part 1 of the
APeX-2 study.
What does this article add to our knowledge? Part 2 of the APeX-2 study conﬁrmed the safety, tolerability, and
effectiveness of berotralstat through 48 weeks of treatment. Patients who were rerandomized from placebo to berotralstat
had substantial declines in hereditary angioedema attack rates.
How does this study impact current management guidelines? As a once-daily oral therapy, berotralstat provides an
effective alternative to current targeted prophylactic therapies for patients with hereditary angioedema that eliminates the
treatment burdens associated with intravenous or subcutaneous administration.
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Abbreviations used
AE- Adverse event
AE-QoL- Angioedema Quality of Life
C1-INH- C1 esterase inhibitor
HAE- Hereditary angioedema
QoL- Quality of life
SAE- Serious adverse event
TEAE- Treatment-emergent adverse event
TSQM- Treatment Satisfaction Questionnaire for Medication

BACKGROUND: Berotralstat (BCX7353) is a recently
approved, oral, once-daily kallikrein inhibitor for hereditary
angioedema (HAE) prophylaxis. In the APeX-2 trial, berotralstat
reduced HAE attack rates over 24 weeks, with a favorable safety
and tolerability proﬁle.
OBJECTIVE: Evaluate berotralstat safety, tolerability, and
effectiveness over 48 weeks.
METHODS: APeX-2 is a phase 3, parallel-group, multicenter trial
(NCT03485911) in patients with HAE due to C1 esterase inhibitor deﬁciency. Part 1 was double-blind and placebo-controlled,
with patients randomized to 24 weeks of berotralstat 150 mg, 110
mg, or placebo. In part 2, patients continued berotralstat the same
dose or, if initially randomized to placebo, were rerandomized to
berotralstat 150 mg or 110 mg through weeks 24 to 48. The primary end point was safety and tolerability.
RESULTS: One hundred eight patients received 1 or more doses
of berotralstat in part 2. Treatment-emergent adverse events
(TEAEs) occurred in 30 of 39 patients (77%) in the placebo
group during part 1, and 25 of 34 patients (74%) re-randomized
from placebo to berotralstat 110 mg or 150 mg in part 2, with
drug-related TEAEs in 13 of 39 (33%), and 11 of 34 (32%) in
the same groups. Most TEAEs were mild or moderate, with no
serious drug-related TEAEs. The most common TEAEs were
upper respiratory tract infections, abdominal pain, diarrhea, and
vomiting. Mean (–standard error of the mean) monthly attack
rates at baseline and week 48 were 3.06 (–0.25) and 1.06 (–0.25)
in the berotralstat 150mg 48-week group and 2.97 (–0.21) and
1.35 (–0.33) in the berotralstat 110mg 48-week group.
CONCLUSIONS: The safety, tolerability, and effectiveness of
berotralstat were maintained over 48 weeks of
treatment. Ó 2021 The Authors. Published by Elsevier Inc. on
behalf of the American Academy of Allergy, Asthma &
Immunology. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/). (J Allergy
Clin Immunol Pract 2021;9:2305-14)
Key words: Hereditary angioedema; HAE; Berotralstat;
BCX7353; Prophylaxis; Phase 3 trial; Kallikrein inhibitor; Oral
therapy; C1 inhibitor

INTRODUCTION
Hereditary angioedema (HAE) due to C1-INH (C1 esterase
inhibitor) deﬁciency is a rare genetic disorder that results
from mutations in the SERPING1 gene. The primary manifestations are recurrent, unpredictable, and potentially disabling
or life-threatening angioedema attacks in the skin or mucosa.1-4
Hereditary angioedema causes a signiﬁcant burden on patients
and impacts quality of life (QoL) for patients and their
families.5-11
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Management of HAE has changed signiﬁcantly in the past
decade; earlier recognition of the disease and the expansion of
available treatments have led to improved management. The
increasing shift toward long-term prophylactic treatment to
reduce the risk of attacks can decrease disease burden and have a
positive impact on quality of life.12 Recent treatment guidelines
recommend that prophylactic therapy should be individualized
by considering factors such as attack frequency, lifestyle, and
patient preferences.13 Until recently, all available targeted prophylactic therapies were administered by either intravenous or
subcutaneous injection, which impose a substantial treatment
burden on patients and their caregivers such as challenges with
needle use and self-administration.12,14 Thus, there is a signiﬁcant unmet need for HAE treatment options that are less
burdensome than the available targeted parenteral prophylactic
therapies. This need could be addressed with an oral medication
that is efﬁcacious and well tolerated, with a more favorable
adverse effect proﬁle than the existing oral agents.
Berotralstat (BCX7353) is a highly selective oral inhibitor of
plasma kallikrein that was recently approved for the prevention
of angioedema attacks in adults and children aged 12 years or
older with HAE.15 Four studies have provided data on the
clinical efﬁcacy and safety of berotralstat for HAE prophylaxis:
the phase 2 APeX-1 trial (NCT02870972), 2 ongoing phase
3
trials—APeX-2
(NCT03485911)
and
APeX-J
(NCT03873116)—and an ongoing long-term safety study,
APeX-S (NCT03472040). In APeX-1, the rate of conﬁrmed
HAE attacks was signiﬁcantly lower among patients receiving
berotralstat than among those receiving placebo.16 In both
APeX-2 and APeX-J, the results from part 1 (the randomized,
double-blind, placebo-controlled portions) demonstrated that
berotralstat signiﬁcantly reduced the rate of HAE attacks
compared with placebo and was generally well tolerated.17-20
Finally, no new safety signals have been seen in the ongoing
APeX-S study.21
The APeX-2 trial part 2 evaluated the safety, tolerability, and
effectiveness of berotralstat through an additional 24 weeks of
blinded active berotralstat treatment. Here we report the results
of part 2 of the APeX-2 trial.

METHODS
Trial design
The APeX-2 is a phase 3, parallel-group, multicenter, 3-part trial
(Figure 1). The study is being conducted at 40 sites in 11 countries
(Table E1; available in this article’s Online Repository at www.jaciinpractice.org). Part 1 was randomized, double-blind, and placebocontrolled with a 24-week treatment period that compared berotralstat 150 mg once-daily and berotralstat 110 mg once-daily with
placebo. The detailed design and ﬁnal results of part 1 are reported
elsewhere.19 Part 2 evaluated the safety and tolerability of berotralstat, as well as effectiveness, QoL, and patient satisfaction with
medication, from week 24 through week 48. In part 2, patients
randomized to placebo in part 1 were rerandomized 1:1 to blinded
active treatment with either berotralstat 150 mg once-daily or berotralstat 110 mg once-daily. Patients initially randomized to active
treatment in part 1 continued on the same dose of blinded active
treatment. All patients, investigators, and site personnel remained
blinded to treatment group allocation in part 2, although all
participants were informed that patients would receive active therapy
in part 2.
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FIGURE 1. APeX-2 study design. QD, Every day.

The trial protocol and other study documents were reviewed and
approved by the relevant regulatory authorities and independent
ethics committees or institutional review boards before enrollment of
any patients. All patients provided written informed consent (assent
for adolescent patients) before undergoing any trial-related procedures. This study was conducted in accordance with the principles of
the Declaration of Helsinki and the International Council for
Harmonisation/Good Clinical Practice. An independent data
monitoring committee provided review of safety data at prespeciﬁed
intervals, with additional consultation or review as needed. This
study was funded by BioCryst Pharmaceuticals, Inc.

Patients
Patients were eligible for inclusion if they were 12 years of age or
older (18 years or older at study sites in Europe), had a clinical
diagnosis of type 1 or 2 HAE, were medically appropriate for ondemand treatment as the sole medical management for HAE
during the study, and had experienced 2 or more investigatorconﬁrmed HAE attacks within 56 days after the screening visit. A
type 1 or 2 HAE diagnosis was deﬁned as having a C1-INH
functional level below 50% and a complement 4 (C4) level below
the lower limit of normal, as assessed during the screening period.
Patients with C1-INH functional level between 50% and 74% or
C4 above the lower limit of normal could be enrolled if they were
qualiﬁed based on alternative criteria, described in the Online
Repository. All patients were required to have access to at least 1
approved on-demand therapy and were to treat HAE attacks in
accordance with their usual treatment plan. Patients who completed
treatment with the study drug in part 1 were eligible to continue
into part 2.

Treatments and randomization
Detailed information on treatment and randomization in part 1 is
presented separately.19
Patients in the berotralstat 150mg or berotralstat 110mg groups
who completed part 1 continued on the same dose in part 2. Patients
in the placebo group who completed part 1 were rerandomized 1:1
to receive either berotralstat 150 mg once-daily or berotralstat 110
mg once-daily for part 2 in a blinded manner. Patients were
randomized centrally using an interactive web response system

(Veracity Logic, Chapel Hill, NC). No stratiﬁcation was applied for
part 2. The 1:1 randomization for part 2 (block size of 4) was
generated using SAS v 9.3 software and uploaded to the interactive
web response system.

Assessments
Patients recorded the frequency, duration, location, functional
impact, and any treatment of HAE attacks experienced in the previous 24 hours in an electronic diary daily. Investigators discussed
each reported attack with the patient within 2 business days after the
event.
The primary objective for part 2 was evaluation of long-term
safety and tolerability. The primary end points included the number and proportion of subjects with treatment-emergent adverse
events (TEAEs), discontinuations due to TEAEs, serious TEAEs,
grade 3 or 4 TEAEs, or laboratory abnormalities, and rash. Relationship to the study drug was assessed by the investigator and
TEAEs considered possibly, probably, or deﬁnitely related were
classiﬁed as treatment related.
Secondary end points included the number and rate of
investigator-conﬁrmed HAE attacks, durability of response (attack
rate trend over time), discontinuations due to lack of efﬁcacy, and
the durability of changes in Angioedema Quality of Life (AE-QoL)
and Treatment Satisfaction Questionnaire for Medication (TSQM)
scores. The AE-QoL is a validated, patient-reported outcome measurement that assesses QoL in 4 dimensions with a total of 17 items;
a higher total score indicates greater QoL impairment (scale: 0e100
points; minimum clinically important difference for improvement is
a reduction of 6 points).22 The TSQM assesses treatment satisfaction across 4 domains (global satisfaction, effectiveness, side effects,
and convenience) with scores ranging from 0 to 100; higher scores
indicate greater satisfaction.23
Investigator-conﬁrmed attacks were included in the analysis.
Investigator conﬁrmation was based on investigator review of diary
data and discussion within 2 days of resolution of the attack between
the patient and the investigator or an appropriately trained designee.
Symptoms of swelling, including symptoms in the oropharyngeal or
abdominal regions indicative of internal swelling, were required for
an attack to be conﬁrmed.
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2 laboratory abnormality
or AE

• 1 laboratory abnormality

or AE

FIGURE 2. Patient disposition in APeX-2 parts 1 and 2. ITT, intention to treat. AE, adverse event *Discontinued study drug early; per
protocol, some patients discontinued study drug but remained on-study through the end of the study part during which they discontinued.

Statistical analyses
All prespeciﬁed analyses were detailed in the statistical analysis
plan. Adverse events (AEs) are reported for the safety population,
which includes all patients who received at least 1 dose of study
medication. The investigator-conﬁrmed attack rate was calculated
for each month (a month was deﬁned as a 28-day period). The total
number of investigator-conﬁrmed HAE attacks experienced in the
period of interest was divided by the number of days in the study
period and multiplied by 28 days/month to report the rate in attacks/month adjusted for the length of a month and the number of
days during the period. If a subject discontinued during a given
period, the attack rate was calculated through the date of discontinuation. Analyses of effectiveness and patient-reported outcomes
were descriptive and were performed on all observed data at time
points up to 48 weeks. A completers analysis was also conducted
utilizing data from only those patients who received study treatment
through week 48. The duration of investigator-conﬁrmed attacks
was calculated in hours, based on the start and stop time of the
attack as reported by the subject. All statistical analyses were conducted using SAS software version 9.4 (SAS Institute Inc., Cary,

NC). Part 2 began with administration of the ﬁrst dose of berotralstat dispensed after the week 24 visit.

RESULTS
Patients
Between March 14, 2018, and October 23, 2018, 160
patients were screened, of whom 121 were randomized and 120
were treated in part 1, as previously reported.19 A total of 108
patients completed study drug dosing in part 1 and received at
least 1 dose of berotralstat in part 2. Of these, 88 completed
dosing in part 2. The last patient completed 48 weeks of dosing
(parts 1 and 2) on September 25, 2019. Figure 2 summarizes
patient dispositions in part 1 and details patient dispositions in
part 2.
Among the 108 patients who were randomized in part 1 and
continued in part 2, 94% were White, 68% were female, and the
mean age was 41.6 years (range 12e72 years). Six patients were
adolescents (range 12e17 years), and 8 were elderly (range
65e74 years). The mean (SD) baseline HAE attack rate was
3.0 (1.4). Patient baseline characteristics were generally similar
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TABLE I. Baseline characteristics; ITT population: patients who transitioned to part 2
Treatment

Characteristic

Mean age at consent, y (SD)
Age at consent, n (%)
12e17 y
18e64 y
65 y
Female sex, n (%)
Race, n (%)*
White
Black or African American
Asian
Other
Mean weight at screening, kg (SD)
Mean BMI at screening, kg/m2 (SD)
Region, n (%)
North America
Europe
Baseline investigator-conﬁrmed attack rate, mean (SD)
2 attacks/month
<2 attacks/month
Any past prophylactic treatment for HAE, n (%)
Any prior androgen use, n (%)†
Any prior prophylactic C1-INH use, n (%)z
Prior prophylactic treatment use within 30 d of
screening, n (%)

Berotralstat
150 mg
(n [ 37)

Berotralstat
110 mg
(n [ 37)

Berotralstat 150 mg
after placebo
(n [ 17)

Berotralstat 110 mg
after placebo
(n [17)

40.7 (14.2)

39.1 (17.3)

45.7 (14.8)

44.8 (14.9)

2
34
1
22

(5.4)
(91.9)
(2.7)
(59.5)

2
31
4
27

35 (94.6)
1 (2.7)
0
1 (2.7)
89.1 (20.4)
30.8 (6.8)
24
13
3.2
29
8
29
20
20
12

(5.4)
(83.8)
(10.8)
(73.0)

35 (94.6)
1 (2.7)
1 (2.7)
0
79.7 (21.9)
27.8 (7.5)

(64.9)
(35.1)
(1.6)
(78.4)
(21.6)
(78.4)
(54.1)
(54.1)
(32.4)

29
8
3.0
26
11
28
17
14
8

(78.4)
(21.6)
(1.3)
(70.3)
(29.7)
(75.7)
(45.9)
(37.8)
(21.6)

1
14
2
13

(5.9)
(82.4)
(11.8)
(76.5)

1
15
1
11

15 (88.2)
1 (5.9)
0
1 (5.9%)
89.2 (21.7)
30.8 (7.2)
12
5
2.8
10
7
12
10
7
4

(5.9)
(88.2)
(5.9)
(64.7)

17 (100.0)
0
0
0
84.1 (23.6)
29.1 (7.0)

(70.6)
(29.4)
(1.4)
(58.8)
(41.2)
(70.6)
(58.8)
(41.2)
(23.5)

12
5
2.9
13
4
14
12
7
6

(70.6)
(29.4)
(0.9)
(76.5)
(23.5)
(82.4)
(70.6)
(41.2)
(35.3)

BMI, Body mass index; C1-INh, C1 esterase inhibitor; ITT, intent to treat (the ITT population included all patients who underwent randomization); SD, standard deviation.
*Race was self-reported.
†Prior androgen use was noted in the patients’ HAE medical and medication history and included any of the following androgens (unspeciﬁed), oxandrolone, methyltestosterone, danazol, and stanozolol.
zC1-INH includes plasma-derived and recombinant C1-INH and fresh frozen plasma.

TABLE II. Overall summary of TEAEs through week 48, safety population
Up to 48 weeks exposure

Up to 24 weeks exposure

Number (%) of Patients with:

150 mg
(n [ 40)

110 mg
(n [ 41)

150 mg after
placebo
(n [ 17)

110 mg after
placebo
(n [ 17)

Placebo
(n [ 39)

Any AE
Any drug-related AE
Any SAE
Any drug-related SAE
Any grade 3 or 4 AE
Any drug-related grade 3 or 4 AE
Any AE leading to discontinuation of study drug
GI abdominal AEs leading to discontinuation of study drug
Any investigator-identiﬁed rash†

38 (95.0)
17 (42.5)
1 (2.5)
0
3 (7.5)
1 (2.5)
3 (7.5)
1 (2.5)
2 (5.0)

38 (92.7)
18 (43.9)
1 (2.4)
0
5 (12.2)
3 (7.3)
4 (9.8)
2 (4.9)
0

12 (70.6)
7 (41.2)
1 (5.9)*
0
1 (5.9)
0
0
0
0

13 (76.5)
4 (23.5)
0
0
1 (5.9)
0
0
0
0

30 (76.9)
13 (33.3)
2 (5.1)
0
3 (7.7)
0
1 (2.6)
0
0

AE, Adverse event; GI, gastrointestinal; SAE, serious adverse event
*Uterine leiomyoma; previously reported as occurring in part 1 in the placebo group.
†An investigator-identiﬁed rash is any AE that the investigator noted as an AE of special interest on the AE case report form.
GI abdominal AE is any AE with a preferred term within the Medical Dictionary for Regulatory Activities (MedDRA) v19.1 hierarchy under the High Level Group Terms of (1)
GI signs and symptoms or (2) GI motility and defecation conditions. TEAEs were deﬁned as any AE after initiation of study drug through wk 48 or the last dose of study drug þ
30 d if the subject discontinued prior to wk 48. Detailed deﬁnitions are presented in the Online Repository.

across all treatment groups, except that patients in the placebo to
berotralstat groups were older, and fewer women were enrolled in
the berotralstat 150mg group (Table I).

Safety
TEAEs were reported by 76 of 81 patients (94%) who were
randomized to berotralstat in parts 1 and 2 (up to 48 weeks of
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(n = 40)

(n = 41)

after

(n = 17)

(n = 17)

after

FIGURE 3. Mean (standard error of the mean [SEM]) investigator-confirmed HAE monthly attack rates at baseline (BL), 24 weeks, 28
weeks, and 48 weeks by treatment arm. Intention to treat (ITT) population. Error bars represent the SEM. Attack rates are for the 4 weeks
preceding each visit.

exposure to berotralstat), by 30 of 39 patients (77%) randomized
to placebo in part 1 (up to 24 weeks of exposure to placebo), and
by 25 of 34 patients (74%) rerandomized from placebo to berotralstat in part 2 (up to 24 weeks of exposure to berotralstat).
Table II summarizes the AEs reported. Most were mild or
moderate in severity. The most common AEs (ie, those reported
during parts 1 and 2 in 10% of patients in any treatment
group) were upper respiratory tract infection, nausea, abdominal
pain, dyspepsia, diarrhea, vomiting, headache, ﬂatulence,
gastroesophageal reﬂux disease, and back pain (Table E2; available in this article’s Online Repository at www.jaci-inpractice.
org). Drug-related AEs were reported by 35 of 81 patients
(43%) who were randomized to berotralstat in parts 1 and 2 (up
to 48 weeks of exposure to berotralstat), by 13 of 39 patients
(33%) randomized to placebo in part 1 (up to 24 weeks of
exposure to placebo), and by 11 of 34 patients (32%)
rerandomized from placebo to berotralstat in part 2 (up to 24
weeks of exposure to berotralstat) (Table II). Ninety-one percent
of the drug-related TEAEs were mild or moderate (grade 1 or 2)
in severity.
Nine percent of TEAEs were grade 3 or 4 in severity. Grade 3 or
4 TEAEs due to any cause were reported by 8 of 81 patients (10%)
randomized to berotralstat in parts 1 and 2, 3 of 39 patients (8%)
randomized to placebo in part 1, and 2 of 34 patients (6%) who
were rerandomized from placebo to berotralstat for part 2. Details
are presented in Table E3 (available in this article’s Online Repository at www.jaci-inpractice.org). Of the 10 patients randomized to berotralstat who reported grade 3 or 4 AEs, 4 patients had a
total of 5 events that were considered drug-related (all grade 3): 3
events previously reported in part 1, and 2 events of grade 3 anal
incontinence in 1 patient receiving berotralstat 150 mg in part 2.
No drug-related grade 4 AEs were reported.
Treatment-emergent serious adverse events (SAEs) occurred in
5 patients in parts 1 and 2: 4 patients previously reported in part

1 and 1 patient in part 2. Details of all SAEs occurring in the
study are presented in the Table E3. In part 2, 1 patient in the
berotralstat 150-mg group underwent medical observation;
the patient was hospitalized according to the local standard of
care for a routine screening procedure (radioactive iodine test)
unrelated to HAE or treatment. There were no drug-related
SAEs in any treatment group.
Seven patients receiving berotralstat discontinued study drug
due to AEs through 48 weeks: 4 in part 1, and 3 in part 2 (2 patients
receiving berotralstat 150 mg due to anal incontinence and palpitations/tachycardia; 1 patient receiving berotralstat 110 mg due
to nausea). In part 2, 17 patients discontinued for reasons other
than AEs (Figure 2), including 10 patients who discontinued for
perceived lack of efﬁcacy: 3 patients receiving berotralstat 150 mg,
5 patients receiving berotralstat 110 mg, and 2 patients who were
rerandomized from placebo to berotralstat 150 mg.

Effectiveness
Signiﬁcant declines in the HAE attack rate were observed in
part 1 as previously reported.19 Attack rates declined further by
the end of part 2 among patients receiving berotralstat 150 mg or
berotralstat 110 mg for the entire 48-week dosing period
(Figure 3). Mean attack rates (standard error of the mean
[SEM]) for the 150mg group declined from 3.06 (0.25) attacks/month at baseline to 1.70 (0.32) at week 24, 1.32
(0.26) at week 28, and 1.06 (0.25) at week 48. For the
110mg group, attack rates were 2.97 (0.21) at baseline, 1.69
(0.36) at week 24, 1.81 (0.34) at week 28, and 1.35 (0.33)
at week 48. The HAE attack rates decreased in part 2 for patients
who rerandomized from placebo to either dose of berotralstat.
The magnitude of the decrease was similar to that observed in
part 1 for patients originally randomized to berotralstat. In the
placebo to berotralstat 150mg group, mean attack rates were
2.83 (0.34) at baseline, 2.56 (0.61) at week 24 (immediately
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B
FIGURE 4. Investigator-confirmed HAE attacks and use of on-demand medication. A, Patients who transitioned to berotralstat 150 mg
after placebo. B, Patients who transitioned to berotralstat 110 mg after placebo. Each horizontal line represents 1 patient. Vertical blue
bars represent HAE attacks and show the duration of each attack. Each dark gray dot above a blue bar represents use of on-demand
therapy. Each red X at the end of a horizontal line represents treatment discontinuation.
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(n = 41)
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Placebo (n = 17)

(n = 41)
placebo (n = 17)
Placebo (n = 17)

FIGURE 5. Mean (SEM) AE-QoL total score by visit week. A decrease represents improvement. Error bars represent the SEM. Dashed
horizontal lines indicate the mimimally clinically important difference from baseline (week 0).

before starting berotralstat), 1.29 (0.41) at week 28 (4 weeks
after starting berotralstat), and 0.57 (0.23) at week 48 (24
weeks after starting berotralstat). In the placebo to berotralstat
110mg group, mean attack rates were 2.86 (0.21) at baseline,
2.39 (0.41) at week 24, 1.29 (0.25) at week 28, and 1.25
(0.32) at week 48.
A completers analysis, including only patients who continued
dosing with study treatment through the week 48 visit, was
performed to address the potential for bias in secular trend in
attack rate arising from differential rates of discontinuation. The
completers analysis found results similar to the primary analysis
results, with further reduction in attack rates from months 6 to
12, indicating that discontinuations had no meaningful impact
on study results (Figure E1; available in this article’s Online
Repository at www.jaci-inpractice.org).
All attacks during screening, part 1, and part 2, including frequency, duration, and use of on-demand treatment, are shown in
Figure 4 for each patient who transitioned from placebo to berotralstat 150 mg or 110 mg in part 2. After the patients started
berotralstat, the frequency and duration of HAE attacks and
patients’ use of on-demand HAE treatment generally declined.

Patient-reported outcomes
Patients on berotralstat in parts 1 and 2 experienced an
improvement in the AE-QoL total score, starting as early as week
4, which was sustained through week 48. For patients who were
rerandomized from placebo to berotralstat, AE-QoL total scores
improved after initiation of berotralstat (Figure 5). Sixty-seven
percent of all berotralstat-treated patients achieved the minimum clinically important difference (MCID) at week 48. In
addition to the assessment of QoL, the effect of berotralstat on
patient satisfaction with treatment was evaluated using the
TSQM, which showed improvements in global satisfaction in
patients who were rerandomized from placebo to berotralstat
(Figure E2; available in this article’s Online Repository at www.
jaci-inpractice.org).
DISCUSSION
The APeX-2 trial evaluated berotralstat for HAE attack prophylaxis using a 3-part design: part 1 evaluated efﬁcacy and safety

by comparing 2 doses of berotralstat with a placebo control
group, and part 2 evaluated safety, tolerability, and effectiveness
without a control group to minimize patients’ time on placebo.
The long-term open-label extension phase of the study (part 3) is
ongoing. Part 2 results conﬁrm the safety and efﬁcacy proﬁles
observed for berotralstat in part 1. The trial enrolled patients
with HAE who represent a wide spectrum of HAE disease
burden and are likely to beneﬁt with prophylaxis. The results are
expected to be generalizable to this patient population.
No new safety signals were identiﬁed in part 2 of the trial.
Berotralstat was well tolerated throughout the trial with no drugrelated SAEs reported. The majority of AEs were mild or moderate. The rate of AEs reported in part 2 by patients in the
berotralstat after placebo groups was similar to the rate reported
by the same patient groups while receiving placebo in part 1.
Over the entire 48-week trial, less than 10% of patients receiving
berotralstat discontinued due to AEs. Note that patients who
were randomized to berotralstat in part 1 had greater duration of
exposure to berotralstat (48 weeks) than patients who were
rerandomized from placebo to berotralstat at week 24 (24
weeks). This longer observation time would be expected to increase the number and subject incidence of TEAEs reported, and
this should be considered when reviewing the data.
Among patients who completed 48 weeks of treatment, mean
attack rates declined by 67% and 52% from baseline to week 48
in the berotralstat 150mg and 110mg groups respectively. In part
2 of the study, the reduction in attack rates observed in part 1
continued or declined further, particularly in the berotralstat
150mg group. The decrease in attack rate observed in part 2 in
both berotralstat groups demonstrates a clear durability of
response to treatment. The continued reduction in attack rates is
an important goal in the treatment of HAE. Among patients who
were rerandomized from placebo to berotralstat, the mean
monthly attack rate declined and remained consistently low
through the 24 weeks of berotralstat therapy in part 2 (week 48:
0.57 attacks/month, 150 mg; 1.25 attacks/month, 110 mg).
Berotralstat is a novel small molecule kallikrein inhibitor
indicated as an oral prophylactic therapy to prevent HAE attacks
in adults and children 12 years and older. Until berotralstat
became available, all targeted prophylactic therapies had been
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parenteral and could impose a treatment burden on patients and
caregivers, with issues related to convenience and logistics such as
refrigeration, transport and disposal of syringes and needles, and
the skills and time required for the complex reconstitution and
administration processes.14,24 In addition, self-administration
may be problematic for needle-phobic patients or those with
venous access issues. A recent study found that the majority of
patients receiving HAE prophylaxis agree that needles and the
injection/infusion process are unpleasant, and many have “bad
veins”, injection site reactions, and/or ﬁnd medication storage
and preparation inconvenient.24 Voice-of-the-patient research
conducted by the U.S. Food and Drug Administration in 2017
found that patients perceive an unmet need for new treatments
with less traumatic routes of administration.25 Additional data
show that, although patients currently receiving prophylaxis for
HAE are generally satisﬁed with their medication, they and their
caregivers would be interested in novel treatments with a less
burdensome and more discreet method of administration.14,24
Because of these difﬁculties, an effective targeted oral prophylactic therapy with a favorable beneﬁt-to-risk proﬁle is a useful
treatment option that improves patient QoL by reducing the
burden of treatment. The patient-reported outcome results of
this study, notably the improvements in the AE-QoL total score
and TSQM global satisfaction score, suggest that berotralstat
improves QoL and patient satisfaction in patients with HAE who
choose prophylactic therapy. Interestingly, although an
improvement in QoL was observed, the improvement was not as
robust as the reduction in attack rates. This may be related to the
large placebo effect observed in the QoL assessments. The cause
of the large placebo effect is not fully understood. Factors that
may have contributed to the placebo effect include the frequent
physician visits and other aspects of clinical trial participation,
and the convenience of oral prophylactic therapy (berotralstat or
placebo) compared with intravenous or subcutaneous prophylactic therapy. These factors would be expected to provide
equivalent QoL improvements for all treatment arms.
The primary study limitation was the relatively small number
of patients in each treatment group, particularly in the groups
who transitioned from placebo to berotralstat. The small sample,
observed placebo effect, and large variance in patient-reported
outcome measures limited the ability to quantitate the effects
of berotralstat on those outcomes.
In many patients with HAE, the disease is managed with lifelong prophylactic therapy. The evidence of effectiveness and
safety through 48 weeks of drug administration in this study
support berotralstat as a beneﬁcial treatment option that should
be considered in treatment decision making.
Berotralstat is an oral, once-daily prophylactic therapy that
demonstrated a sustained and clinically signiﬁcant reduction in
HAE attack rates for 48 weeks in this study, with a favorable
balance of efﬁcacy and safety. Berotralstat provides a simple,
once-daily, oral alternative to current injectable prophylactic
therapies for patients with HAE.
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ONLINE REPOSITORY
Trial design and data collection
B. L. Zuraw, W. P. Sheridan, S. C. Murray, D. T. Johnston,
E. Aygören-Pürsün, J. Bernstein, W. R. Lumry, T. Craig, and H.
A. Iocca, participated in the design of the study, design of study
instruments, and planning of statistical analyses. B. L. Zuraw, J.
M. Best, B. Desai, H. A. Iocca, E. Nagy, S. C. Murray, and W.
P. Sheridan were involved with formal data analysis, methodology, project administration, and supervision. S. C. Murray was
the lead study statistician. D. T. Johnston, W. R. Lumry, E.
Aygören-Pürsün, J. Bernstein, J. S. Jacobs, R. Gower, H. J.
Wedner, T. Craig, and S. Kiani-Alikhan were study investigators
participating in the conduct of the study, including the recruitment and follow-up of patients (Table E1). All authors participated in the review and revision of the manuscript and approved
the ﬁnal draft.
Detailed inclusion/exclusion criteria
Subjects were required to meet all of the following criteria to
be eligible for the study.
1. Males and nonpregnant, nonlactating females 18 years of age
or older (main study) or 12 to 17 years of age (substudy).
2. Able to provide written, informed consent. Subjects who are
aged 12 to 17 years of age at screening for the substudy must
be able to read, understand, and willing to sign an assent form
in addition to a caregiver providing informed consent.
3. Subject weight of 40 kg or greater.
4. A clinical diagnosis of hereditary angioedema (HAE) type 1 or
2, deﬁned as having a C1 esterase inhibitor (C1-INH)
functional level below 50% and a complement 4 (C4) level
below the lower limit of the normal (LLN) reference range, as
assessed during the screening period. In the absence of a low
C4 value drawn during the intercritical period (ie, subject is
not having an HAE attack), 1 of the following is acceptable to
conﬁrm the diagnosis of HAE: (a) a SERPING-1 gene mutation known or likely to be associated with HAE type 1 or 2
assessed during the screening period; (b) a conﬁrmed family
history of C1-INH deﬁciency; (c) a C4 redrawn and retested
during an attack in the screening period with the results below
the LLN reference range.
For subjects with C1-INH function 50% or greater but less
than the assay LLN, a SERPING-1 gene mutation known or
likely to be associated with HAE type 1 or 2, as assessed during
the screening period OR a repeat C1-INH functional level less
than 50% was considered acceptable for enrollment.
5. Access to and ability to use 1 or more acute medications
approved by the relevant competent authority for the
treatment of acute attacks of HAE (icatibant, plasma-derived
C1-INH, ecallantide, or recombinant C1-INH). Cinryze
used for acute treatment of HAE attacks is an acceptable
medication for this purpose.
6. Subjects must be medically appropriate for on-demand
treatment as the sole medicinal management for their
HAE during the study.
7. The subject must have at least 2 HAE attacks that meet all of
the requirements that follow during the run-in period of a
maximum of 56 days from the screening visit:
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 The attacks are unique, which is deﬁned as an attack that
does not begin within 48 hours of the end of a previous
attack.
 The attacks must either have been treated, have required
medical attention, or be documented to cause functional
impairment based on subject entry in the diary. Functional impairment is deﬁned as the subject being unable to
perform their daily activities without restriction (ie, subject records that they are at least slightly restricted in their
daily activities during their HAE attack).
 The attacks must include symptoms of swelling. Symptoms of swelling, in addition to visible swelling, may also
include symptoms in the oropharyngeal or abdominal
regions that are indicative of internal swelling.
 The attacks are conﬁrmed by the investigator to be HAE
attacks. Subjects will be contacted within 2 business days
of the attack to discuss the attack, any queries on the
entered data in the e-diary, as applicable.
 Subjects who have recorded 2 such attacks may be randomized to the study drug beginning on or after day 28 of
the run-in period; subjects who have recorded at least 3
such attacks may be randomized to the study drug
beginning on or after day 14 of the run-in period. Under
no circumstances should the run-in attack requirement for
eligibility be disclosed to the study subjects.
8. Female subjects must meet at least 1 of the following
requirements:
 Be a woman of childbearing potential (deﬁned as a nonmenopausal adult or adolescent female who has not had a
hysterectomy, bilateral oophorectomy, or documented
ovarian failure) who agrees to use at least an acceptable
effective contraceptive method during the study and for a
duration of 30 days after the last dose of the study drug.
 Female subjects of childbearing potential who declare
themselves as either sexually abstinent or exclusively
having female sexual partners do not need to use an
acceptable method of contraception. Abstinence in this
study is deﬁned as “true abstinence: when this is in line
with the preferred and usual lifestyle of the subject."
 Be a woman of non-childbearing potential (deﬁned as
postmenopausal for 2 or more years or having a folliclestimulating hormone greater than 40 mIU/mL if postmenopausal 2 years or less or have had a hysterectomy,
bilateral oophorectomy, or documented ovarian failure).
9. Male subjects must comply with the following requirements
through the end of the study:
 Subjects with female partners of childbearing potential
(deﬁned as postmenopausal 2 years or less or a nonmenopausal female who has not had a hysterectomy,
bilateral oophorectomy, or documented ovarian failure)
must agree to utilize at least 1 acceptably effective contraceptive method.
 Male subjects who declare themselves as sexually abstinent
are acceptable for the purposes of this study. Abstinence in
this study is deﬁned as “true abstinence: when this is in
line with the preferred and usual lifestyle of the subject.”
10. In the opinion of the investigator, the subject is expected to
adequately comply with all required study procedures for the
duration of the study. The subject must demonstrate
adequate compliance with all study procedures required
from the screening visit through randomization, including
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diary recording of HAE attacks beginning at the screening
visit.

Exclusion criteria
Patients were excluded if any of the following conditions were
present.
1. Any clinically signiﬁcant medical or psychiatric condition or
medical history that, in the opinion of the investigator or
sponsor, would interfere with the subject’s ability to
participate in the study or increases the risk to the subject by
participating in the study.
2. Dementia, altered mental status, or any psychiatric condition, or stay in an institution further to an ofﬁcial or court
order that would prohibit the understanding or rendering of
informed consent or participation in the study.
3. Anticipated use of short-term prophylaxis of angioedema
attacks for a preplanned procedure during the screening or
study periods (parts 1 and 2 only).
4. Concurrent diagnosis of any other type of recurrent
angioedema.
5. Clinically signiﬁcant abnormal electrocardiogram at the
screening visit. This includes, but is not limited to, a
QT interval corrected by Fridericia formula (QTcF)
greater than 470 ms for women, a QTcF greater than
450 ms for men, PR interval greater than 220 ms (both
sexes), or ventricular and/or atrial premature contractions
that are more frequent than occasional and/or as couplets
or higher in grouping.
6. Any clinically signiﬁcant history of angina, myocardial
infarction, syncope, clinically signiﬁcant cardiac arrhythmias,
left ventricular hypertrophy, cardiomyopathy, or any other
clinically signiﬁcant cardiovascular abnormality such as
poorly controlled hypertension.
7. Known family history of sudden cardiac death. Family history of sudden death from HAE is not exclusionary.
8. History of or current implanted deﬁbrillator or pacemaker.
9. Any abnormal laboratory or urinalysis parameter at screening
that, in the opinion of the investigator, is clinically signiﬁcant and relevant for this study. A calculated creatinine
clearance of 30 mL/min or less or aspartate transaminase or
alanine transaminase value 3 or more  the upper limit of
the normal reference range value obtained during screening
is exclusionary.
10. Prior enrollment in a berotralstat (BCX7353) study.
11. Suspected C1-INH resistance in the opinion of the investigator or sponsor.
12. History of alcohol or drug abuse within the previous year
prior to the screening visit, or current evidence of substance
dependence or abuse (self-reported alcoholic intake > 3
drinks/d).
13. Positive serology for human immunodeﬁciency virus or
current infection with hepatitis B virus or hepatitis C virus.
14. Pregnant, planning to become pregnant during the study, or
nursing.
15. Positive drugs of abuse screen (unless drug is used as medical
treatment with a prescription).
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16. History of severe hypersensitivity to multiple medicinal
products or severe hypersensitivity/anaphylaxis with unclear
etiology.
17. Use of androgens or tranexamic acid for prophylaxis of HAE
attacks within the 28 days prior to the screening visit or
initiation during the study. Prophylaxis is deﬁned as
administration of a medication in the absence of symptoms
of an HAE attack.
18. Use of C1-INH for prophylaxis of HAE attacks within the
14 days prior to the screening visit or initiation during the
study. Use of a C1-INH therapy for treatment of attacks is
not excluded at any time, nor is C1-INH for preprocedure
prophylaxis for an unplanned/unforeseen procedure. Prophylaxis is deﬁned as administration of a medication in the
absence of symptoms of an HAE attack.
19. Use of concomitant medications that are metabolized by
cytochrome P450 (CYP) 2D6, CYP2C9, CYP2C19, and
CYP3A4 and have a narrow therapeutic range, within 7 days
of the baseline visit or planned initiation during the study.
20. Use of a medication that is clinically known to prolong the
QT interval and is metabolized by CYP2D6, CYP2C9,
CYP2C19, and/or CYP3A4 7 days prior to the baseline visit
or planned initiation during the study.
21. Use of a medication that is transported by p-glycoprotein
efﬂux pump and has a narrow therapeutic range, within 7
days of the baseline visit or planned initiation during the
study.
22. Use of an angiotensin-converting enzyme inhibitor within 7
days of the baseline visit or planned initiation during the
study.
23. Initiation of an estrogen-containing hormonal contraceptive
within 56 days of the screening visit or planned initiation
during the study (parts 1 and 2 only). Established use
(initiation  56 days prior to screening) during the study is
permitted.
24. Current participation in any other investigational drug study
or received another investigational drug within 30 days of
the screening visit.
25. An immediate family relationship to either sponsor employees, the investigator, or employees of the study site
named on the delegation log.
26. Held in an institution by a government or judicial order.

Safety data
Definitions for the adverse events tables
Adverse events (AEs) are coded using the Medical Dictionary
for Regulatory Activities (MedDRA) v19.1.
Treatment-emergent adverse events (TEAEs) are deﬁned as
those events that occur after initiation of the study drug through
week 48 or the last dose of study drug plus 30 days if the patient
discontinued prior to week 48.
A drug-related TEAE is deﬁned as any AE in which the
investigator deﬁnes the relationship as possibly related, probably
related, or deﬁnitely related.
Effectiveness outcomes
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TABLE E1. List of study investigators and locations
Investigator name

FIGURE E1. Mean (standard error of the mean [SEM])
investigator-confirmed attack rate at baseline (BL), 24 weeks, 28
weeks, and 48 weeks by treatment arm in patients who
completed dosing to week 48. Error bars represent the SEM.
Attack rates are for the 4 weeks preceding each visit.

Patient-reported outcomes

FIGURE E2. Mean (SEM) Treatment Satisfaction Questionnaire
for Medication (TSQM) global satisfaction scores by visit week
among patients rerandomized from placebo to berotralstat. An
increase indicates greater satisfaction. Error bars represent the
SEM.

United States
Anderson, John
Banerji, Aleena
Bernstein, Jonathan
Busse, Paula
Craig, Timothy
Diaz, Joseph
Fritz, Stephen
Gower, Richard
Jacobs, Joshua
Johnston, Douglas T.
Li, H. Henry
Lumry, William T.
McNeil, Donald
Mumneh, Nayla
Otto, William
Riedl, Marc
Shapiro, Ralph
Sitz, Karl
Soteres, Daniel
Tachdjian, Rafﬁ
Wedner, H. James
Canada
Gagnon, Remi
Sussman, Gordon
Yang, William
Europe
Aygören-Pürsün, Emel
Bara, Noemi
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TABLE E2. TEAEs (medical concepts) occurring in  10% of patients in any berotralstat group
Up to 48 weeks exposure
150 mg
(n [ 40) n (%)

Medical concept

Upper respiratory tract infection*
Nausea
Abdominal pain*
Dyspepsia
Diarrhea*
Vomiting
Headache
Flatulence
Back pain
Gastroesophageal reﬂux disease

21
8
12
5
7
6
5
3
5
2

110 mg
(n [ 41) n (%)

(52.5)
(20.0)
(30.0)
(12.5)
(17.5)
(15.0)
(12.5)
(7.5)
(12.5)
(5.0)

15
8
4
4
5
4
4
3
2
4

(36.6)
(19.5)
(9.8)
(9.8)
(12.2)
(9.8)
(9.8)
(7.3)
(4.9)
(9.8)

Up to 24 weeks exposure
150 mg
after placebo
(n [ 17) n (%)

3
3
2
2
1
2
0
2
0
2

110 mg
after placebo
(n [ 17) n (%)

(17.6)
(17.6)
(11.8)
(11.8)
(5.9)
(11.8)
(0.0)
(11.8)
(0.0)
(11.8)

4
1
2
1
0
0
0
0
0
0

(23.5)
(5.9)
(11.8)
(5.9)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)

Placebo
(n [ 39) n (%)

11
7
4
3
0
1
2
1
1
0

(28.2)
(17.9)
(10.3)
(7.7)
(0.0)
(2.6)
(5.1)
(2.6)
(2.6)
(0.0)

*The terms Upper respiratory tract infection, Abdominal pain, and Diarrhea are medical concepts that contain multiple preferred terms. Upper respiratory tract infection contains
the preferred terms Nasopharyngitis, Upper respiratory tract infection, and Viral upper respiratory tract infection. Abdominal pain contains the preferred terms Abdominal pain,
Abdominal discomfort, Abdominal pain upper, and Abdominal tenderness. Diarrhea contains the preferred terms Diarrhea and Frequent bowel movements.

TABLE E3. Grade 3 or 4 TEAEs through week 48, safety population
Up to 48 weeks exposure

AE

150 mg (n [ 40)
n (%)

110 mg (n [ 41)
n (%)

Any grade 3 or 4 AE
GI disorders

3 (7.5)
5 (12.2)
1 (2.5)
3 (7.3)
1 patient with 2 episodes 2 patients abdominal pain,
of
1
anal incontinence
patient with 2 episodes
of toothache
Infections and infestations
–
1 (2.4)
Oral herpes
Neoplasms
–
1 (2.4)
Plasma cell myeloma*
1 (2.5)
–
General disorders and
administration site
Chest pain
conditions
Investigations
1 (2.5)
–
Medical observation*z
Musculoskeletal and
1 (2.5)
–
connective tissue
Back pain
disorders
Nervous system disorders
–
–

Skin and subcutaneous
tissue disorders

–

1 (2.4)
Purpura

Up to 24 weeks exposure
150 mg after placebo
(n [ 17)
n (%)

1 (5.9)
–

–
1 (5.9)
Uterine leiomyoma*
–

110 mg after
placebo (n [ 17)
n (%)

1 (5.9)
1 (5.9)
Large intestine polyp

–
–
–

–

–

–

–

–

–

–

–

Placebo (n [ 39)
n (%)

3 (7.7)
1 (2.6)
Diverticulum
intestinal
hemorrhagic*†
1 (2.6)
Pneumonia
–
–

1 (2.6)
GGT increased
–

1 (2.6)
Transient ischemic
attack*†
–

GGT, Gamma-glutamyltransferase; GI, gastrointestinal.
*Serious adverse event (SAE).
†Diverticulum intestinal hemorrhagic and transient ischemic attack occurred in the same patient.
zThis medical observation was the only SAE reported during part 2. Per the local standard of care, the patient was hospitalized for a routine screening procedure.

